Trial Profile

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (DAHLIA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC 1245 (Primary)
Indications Lymphoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms DAHLIA

Most Recent Events

03 Dec 2024 According to a Recursion Pharmaceuticals media release, the first patient has been dosed in Phase 1/2 clinical trial of REC-1245
20 Nov 2024 According to a Recursion Pharmaceuticals media release, dose-escalation data update from this study expected in H1 2026.
07 Nov 2024 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com